287 related articles for article (PubMed ID: 25933503)
1. Time course of appropriate implantable cardioverter-defibrillator therapy and implications for guideline-based driving restrictions.
Kim MH; Zhang Y; Sakaguchi S; Goldberger JJ;
Heart Rhythm; 2015 Aug; 12(8):1728-36. PubMed ID: 25933503
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M
Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360
[TBL] [Abstract][Full Text] [Related]
3. Antitachycardia pacing for shock prevention in patients with hypertrophic cardiomyopathy and ventricular tachycardia.
Dallaglio PD; di Marco A; Moreno Weidmann Z; Perez L; Alzueta J; García-Alberola A; Fernandez-Lozano I; Díaz-Infante E; Rodriguez A; Basterra N; Calvo D; Rodriguez Garcia M; Aceña M; Anguera I
Heart Rhythm; 2020 Jul; 17(7):1084-1091. PubMed ID: 32113896
[TBL] [Abstract][Full Text] [Related]
4. Reassessing the role of antitachycardia pacing in fast ventricular arrhythmias in primary prevention implantable cardioverter-defibrillator recipients: Results from MADIT-RIT.
Schuger C; Daubert JP; Zareba W; Rosero S; Yong P; McNitt S; Kutyifa V
Heart Rhythm; 2021 Mar; 18(3):399-403. PubMed ID: 33232811
[TBL] [Abstract][Full Text] [Related]
5. Normalization of Left Ventricular Ejection Fraction and Incidence of Appropriate Antitachycardia Therapy in Patients With Implantable Cardioverter Defibrillator for Primary Prevention of Sudden Death.
House CM; Nguyen D; Thomas AJ; Nelson WB; Zhu DW
J Card Fail; 2016 Feb; 22(2):125-32. PubMed ID: 26522819
[TBL] [Abstract][Full Text] [Related]
6. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
[TBL] [Abstract][Full Text] [Related]
7. Effect of ICD Therapies on Mortality in the OMNI Trial.
Sun S; Johnson J; Degroot P; Brown ML; Obel O
J Cardiovasc Electrophysiol; 2016 Feb; 27(2):192-9. PubMed ID: 26501695
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA
Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators.
Betensky BP; Tschabrunn CM; Zado ES; Goldberg LR; Marchlinski FE; Garcia FC; Cooper JM
Heart Rhythm; 2012 Jun; 9(6):884-91. PubMed ID: 22338670
[TBL] [Abstract][Full Text] [Related]
11. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
12. Management of pace-terminated ventricular arrhythmias.
Pokorney SD; Al-Khatib SM
Card Electrophysiol Clin; 2015 Sep; 7(3):497-513. PubMed ID: 26304530
[TBL] [Abstract][Full Text] [Related]
13. Programming implantable cardioverter-defibrillator in primary prevention: Guideline concordance and outcomes.
Ananwattanasuk T; Tanawuttiwat T; Chokesuwattanaskul R; Lathkar-Pradhan S; Barham W; Oral H; Thakur RK; Jongnarangsin K
Heart Rhythm; 2020 Jul; 17(7):1101-1106. PubMed ID: 32058014
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention.
Hayashi T; Fukamizu S; Hojo R; Komiyama K; Tanabe Y; Tejima T; Soejima K; Nishizaki M; Hiraoka M; Ako J; Momomura S; Sakurada H
Europace; 2013 Oct; 15(10):1507-15. PubMed ID: 23603305
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Importance of Defibrillator-Appropriate Shocks and Antitachycardia Pacing in Patients With Mild Heart Failure.
Biton Y; Daimee UA; Baman JR; Kutyifa V; McNitt S; Polonsky B; Zareba W; Goldenberg I
J Am Heart Assoc; 2019 Mar; 8(6):e010346. PubMed ID: 30857452
[TBL] [Abstract][Full Text] [Related]
16. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients.
Sweeney MO; Sherfesee L; DeGroot PJ; Wathen MS; Wilkoff BL
Heart Rhythm; 2010 Mar; 7(3):353-60. PubMed ID: 20185109
[TBL] [Abstract][Full Text] [Related]
17. Clinical course and prognostic relevance of antitachycardia pacing-terminated ventricular tachyarrhythmias in implantable cardioverter-defibrillator patients.
Kleemann T; Strauss M; Kouraki K; Zahn R
Europace; 2015 Jul; 17(7):1068-75. PubMed ID: 25687746
[TBL] [Abstract][Full Text] [Related]
18. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial.
Sweeney MO; Wathen MS; Volosin K; Abdalla I; DeGroot PJ; Otterness MF; Stark AJ
Circulation; 2005 Jun; 111(22):2898-905. PubMed ID: 15927965
[TBL] [Abstract][Full Text] [Related]
19. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
